 |
|
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura,
Clin Mol Hepatol. 2022;28(3):575-579. Published online 2022 Apr 21 DOI: https://doi.org/10.3350/cmh.2022.0047
|
|
Citations to this article as recorded by
 A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma
Chih-Lang Lin, Kung-Hao Liang, Ching-Chih Hu, Cheng-Hung Chien, Li-Wei Chen, Rong-Nan Chien, Yang-Hsiang Lin, Chau-Ting Yeh
International Journal of Molecular Sciences.2023; 24(2): 1681. CrossRef Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Clinical and Molecular Hepatology.2023; 29(2): 242. CrossRef Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC
Wang Yao, Ran Wei, Jia Jia, Wang Li, Mengxuan Zuo, Shuqing Zhuo, Ge Shi, Peihong Wu, Chao An
Therapeutic Advances in Medical Oncology.2023; 15: 175883592311638. CrossRef Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
Clinical and Molecular Hepatology.2023; 29(3): 593. CrossRef
|